|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00050752 |
Purpose
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine:
People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Participants will undergo tests and procedures that may include the following:
Blood tests for:
When the tests are completed, participants will discuss the results with a doctor and possibly a genetic nurse or genetic counselor. The genetic findings will not be revealed to participants because their meaning and implications may not yet be understood. Participants may be asked to return to NIH from every 3 months to every 3 years, depending on their condition, for follow-up examinations and tests.
| Condition |
|---|
|
Leiomyomatosis Kidney Neoplasms |
| Study Type: | Observational |
| Official Title: | Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer |
| Estimated Enrollment: | 650 |
| Study Start Date: | December 2002 |
Background:
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma.
HLRCC is caused by mutations in the Krebs cycle enzyme, fumarate hydratase localized on chromosome 1q42.3-q43.
Objectives:
Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome
Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC.
Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations.
Determine genotype/phenotype correlations.
Determine if other genes caused HLRCC.
Eligibility:
An individual from a family in which one or more family members have:
Cutaneous leiomyoma and kidney cancer.
Cutaneous leiomyoma and uterine leiomyoma.
Multiple cutaneous leiomyoma.
Kidney cancer and uterine leiomyomata.
Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/ or Papillary, Type II.
Design:
These rare families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors.
Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.
We will determine if there is a relationship between mutation and disease phenotype.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome and their family members of any age will be recruited from the dermatology, urology, oncology, and genetics communities worldwide.
An individual from a family in which one or more family member have:
Spouses enrolled primarily for linkage analysis
EXCLUSION CRITERIA:
Persons unable to give informed consent.
Contacts and Locations| Contact: NCI Referral Office | 1-888-NCI-1937 |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Sub-Investigator: National Cancer Institute Referral Office For more information at the NIH Clinical Center contact | |
| NCI Frederick Cancer Research Center | Recruiting |
| Frederick, Maryland, United States, 21702-1201 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00050752 History of Changes |
| Obsolete Identifiers: | NCT00055627 |
| Other Study ID Numbers: | 030066, 03-C-0066 |
| Study First Received: | December 17, 2002 |
| Last Updated: | February 3, 2012 |
| Health Authority: | United States: Federal Government |
|
Fibroid Kidney Cutaneous Carcinoma Tumor |
|
Neoplasms Carcinoma, Renal Cell Kidney Neoplasms Disease Susceptibility Genetic Predisposition to Disease Leiomyomatosis Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Disease Attributes Pathologic Processes Leiomyoma Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue |